• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjpharmLink to Publisher's site
Br J Pharmacol. Aug 1996; 118(7): 1848–1854.
PMCID: PMC1909857

Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide.

Abstract

1. The isometric response to arginine-vasopressin (10(-10)-10(-7)M) was studied in 2 mm long rabbit arterial segments isolated from several vascular beds (cutaneous, pial, renal, coronary, muscular, mesenteric and pulmonary). 2. Vasopressin induced contraction in central ear (cutaneous), basilar (pial), renal, coronary and saphenous (muscular) arteries, but had no effect in mesenteric and pulmonary arteries; the order of potency for the contraction was: ear > basilar > renal > coronary > saphenous arteries. 3. Treatment with the blocker of nitric oxide synthesis NG-nitro-L-arginine methyl ester (L-NAME; 10(-6)-10(-4) M) increased significantly (P < 0.05) the contraction to vasopressin in ear (148% of control), basilar (150% of control), renal (304% of control), coronary (437% of control) and saphenous (235% of control) arteries. Removal of the endothelium increased significantly (P < 0.05) the contraction to vasopressin in basilar (138% of control), renal (253% of control), coronary (637% of control) and saphenous (662% of control) arteries, but not in ear artery. Mesenteric and pulmonary arteries in the presence of L-NAME or after endothelium removal did not respond to vasopressin, as occurred in control conditions. 4. The specific antagonist for V1 vasopressin receptors d(CH2)5Tyr(Me)AVP (3 x 10(-9)-10(-7) M) was more potent (pA2 = 9.3-10.1) than the antagonist for both V1 and V2 vasopressin receptors desGly-d(CH2)5-D-Tyr(Et)ValAVP (10(-7)-10(-6) M) (pA2 = 7.4-8.4) to block the contraction to vasopressin of ear, basilar, renal and coronary arteries. 5. The specific V2 vasopressin agonist [deamino-Cys1, D-Arg8]-vasopressin (desmopressin) (10(-10)-10(-7) M) did not produce any effect in any effect in any of the arteries studied, with or without endothelium. 6. In arteries precontracted with endothelin-1, vasopressin or desmopressin did not produce relaxation. 7. These results suggest: (a) most arterial beds studied (5 of 7) exhibit contraction to vasopressin with different intensity; (b) the vasoconstriction to this peptide is mediated mainly by stimulation of V1 vasopressin receptors, and (c) endothelial nitric oxide may inhibit the vasoconstriction to this peptide, especially in coronary and renal vasculatures.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aki Y, Tamaki T, Kiyomoto H, He H, Yoshida H, Iwao H, Abe Y. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. J Cardiovasc Pharmacol. 1994 Feb;23(2):331–336. [PubMed]
  • ARUNLAKSHANA O, SCHILD HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. [PMC free article] [PubMed]
  • Fernández N, García JL, García-Villalón AL, Monge L, Gómez B, Diéguez G. Cerebral blood flow and cerebrovascular reactivity after inhibition of nitric oxide synthesis in conscious goats. Br J Pharmacol. 1993 Sep;110(1):428–434. [PMC free article] [PubMed]
  • García JL, Fernández N, García-Villalón AL, Monge L, Gómez B, Diéguez G. Effects of nitric oxide synthesis inhibition on the goat coronary circulation under basal conditions and after vasodilator stimulation. Br J Pharmacol. 1992 Jul;106(3):563–567. [PMC free article] [PubMed]
  • Gardiner SM, Compton AM, Kemp PA, Bennett T. Effects of NG-nitro-L-arginine methyl ester or indomethacin on differential regional and cardiac haemodynamic actions of arginine vasopressin and lysine vasopressin in conscious rats. Br J Pharmacol. 1991 Jan;102(1):65–72. [PMC free article] [PubMed]
  • Gopalakrishnan V, Xu YJ, Sulakhe PV, Triggle CR, McNeill JR. Vasopressin (V1) receptor characteristics in rat aortic smooth muscle cells. Am J Physiol. 1991 Dec;261(6 Pt 2):H1927–H1936. [PubMed]
  • Heyndrickx GR, Boettcher DH, Vatner SF. Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol. 1976 Nov;231(5 Pt 1):1579–1587. [PubMed]
  • Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol. 1986 Aug;30(2):171–177. [PubMed]
  • Katusić ZS. Endothelial L-arginine pathway and regional cerebral arterial reactivity to vasopressin. Am J Physiol. 1992 May;262(5 Pt 2):H1557–H1562. [PubMed]
  • Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res. 1984 Nov;55(5):575–579. [PubMed]
  • Liard JF, Dériaz O, Schelling P, Thibonnier M. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol. 1982 Nov;243(5):H663–H669. [PubMed]
  • Lluch S, Conde MV, Diéguez G, López de Pablo AL, González MC, Estrada C, Gómez B. Evidence for the direct effect of vasopressin on human and goat cerebral arteries. J Pharmacol Exp Ther. 1984 Mar;228(3):749–755. [PubMed]
  • Martín de Aguilera E, Vila JM, Irurzun A, Martínez MC, Martínez Cuesta MA, Lluch S. Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke. 1990 Dec;21(12):1689–1693. [PubMed]
  • Mather HM, Ang V, Jenkins JS. Vasopressin in plasma and CSF of patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):216–219. [PMC free article] [PubMed]
  • Maturi MF, Martin SE, Markle D, Maxwell M, Burruss CR, Speir E, Greene R, Ro YM, Vitale D, Green MV, et al. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation. 1991 Jun;83(6):2111–2121. [PubMed]
  • Naitoh M, Suzuki H, Murakami M, Matsumoto A, Ichihara A, Nakamoto H, Yamamura Y, Saruta T. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs. Am J Physiol. 1993 Oct;265(4 Pt 2):R934–R942. [PubMed]
  • Schmid PG, Abboud FM, Wendling MG, Ramberg ES, Mark AL, Heistad DD, Eckstein JW. Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol. 1974 Nov;227(5):998–1004. [PubMed]
  • Sigmon DH, Beierwaltes WH. Angiotensin II: nitric oxide interaction and the distribution of blood flow. Am J Physiol. 1993 Dec;265(6 Pt 2):R1276–R1283. [PubMed]
  • Takayasu M, Kajita Y, Suzuki Y, Shibuya M, Sugita K, Ishikawa T, Hidaka H. Triphasic response of rat intracerebral arterioles to increasing concentrations of vasopressin in vitro. J Cereb Blood Flow Metab. 1993 Mar;13(2):304–309. [PubMed]
  • Vanner S, Jiang MM, Brooks VL, Surprenant A. Characterization of vasopressin actions in isolated submucosal arterioles of the intestinal microcirculation. Circ Res. 1990 Oct;67(4):1017–1026. [PubMed]
  • Walker BR, Haynes J, Jr, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol. 1989 Aug;257(2 Pt 2):H415–H422. [PubMed]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...